GLP-1 Medications and Male Fertility: Potential Impact Explored

Recent research indicates that GLP-1 medications, primarily used for weight loss, may enhance male fertility. Experts presented these findings at ENDO 2026, the Endocrine Society’s annual conference in Chicago. The study reveals a significant link between obesity and fertility problems in men.

Obesity and Hormonal Dysregulation

Excess weight can disrupt the hypothalamic-pituitary-gonadal (HPG) axis, which controls testosterone production. This disruption often leads to functional hypogonadism, characterized by abnormally low testosterone levels due to hormone signaling issues. Such hormonal changes can adversely affect semen quality.

Impact of GLP-1 on Reproductive Health

Researchers analyzed the influence of GLP-1 weight-loss drugs on reproductive hormones and metabolic outcomes in men aged 18 to 65. The analysis covered five randomized controlled trials, focusing on testosterone levels, brain hormones linked to testosterone and sperm production, and proteins that transport sex hormones in the blood. Emphasis was also placed on semen quality, BMI, cholesterol, and blood sugar levels.

The results suggested that GLP-1 medications do not suppress male hormones. For obese men with low testosterone levels due to obesity, these drugs may enhance testosterone, sperm quality, and metabolic health, especially during weight loss.

Specific Study Findings

One study over four weeks revealed that dulaglutide had no significant impact on reproductive hormones or sexual function. However, a separate 16-week trial showed liraglutide improved hormonal balance in obese men suffering from functional hypogonadism, suggesting low testosterone is often obesity-related. This study found liraglutide more beneficial for health outcomes than hormone replacement therapy.

Another research cited enhancements in sperm concentration and count with liraglutide use. The authors concluded, “GLP-1s do not appear to acutely suppress the male HPG axis and may improve reproductive hormones and semen parameters in obese hypogonadal men, largely within the context of weight loss.”

In a 24-week study, semaglutide, known as Ozempic and Wegovy, demonstrated improvements in sperm morphology and bad cholesterol levels, while maintaining total testosterone.

Need for Further Research

Despite these promising findings, only five trials have been studied, indicating a need for more research to establish further associations. The authors highlight the necessity for larger randomized controlled trials to better assess male reproductive outcomes.

Dr. Anthony Puopolo, a men’s health expert, discussed these results with Fox News Digital. He noted that the research provides initial evidence suggesting GLP-1 medications offer potential benefits for obese men with hypogonadism and low testosterone levels.

While more extensive studies are required, Dr. Puopolo expressed optimism about the role GLP-1s might play in enhancing male fertility. He suggested that if evidence continues to accumulate, GLP-1s could surpass testosterone replacement therapy in treating low testosterone, preserving fertility where usual therapies may harm reproductive or sperm function.

Angelica Stabile contributed as the lifestyle reporter for Fox News Digital.